Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.08 CAD | 0.00% | 0.00% | +23.08% |
03-27 | MediPharm Labs Narrows Q4 Loss, Revenue Grows; Up 10.5% | MT |
03-27 | MediPharm Labs Narrows Q4 Loss, Revenue Grows | MT |
Sales 2024 * | 43.06M 31.56M | Sales 2025 * | 58.43M 42.82M | Capitalization | 32.32M 23.69M |
---|---|---|---|---|---|
Net income 2024 * | -7M -5.13M | Net income 2025 * | -1M -733K | EV / Sales 2024 * | 0.75 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.55 x |
P/E ratio 2024 * |
-5.33
x | P/E ratio 2025 * |
-
| Employees | 166 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.52% |
Latest transcript on MediPharm Labs Corp.
3 months | +23.08% | ||
6 months | +6.67% | ||
Current year | +23.08% |
Managers | Title | Age | Since |
---|---|---|---|
David Pidduck
CEO | Chief Executive Officer | - | 22-04-19 |
Greg Hunter
DFI | Director of Finance/CFO | - | 21-02-07 |
Keith Strachan
PSD | President | - | 18-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Bumby
BRD | Director/Board Member | 60 | 23-03-31 |
David Pidduck
CEO | Chief Executive Officer | - | 22-04-19 |
Shelley Martin
BRD | Director/Board Member | - | 20-06-21 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.83% | 35 M€ | +18.97% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 0.08 | 0.00% | 228,800 |
24-04-25 | 0.08 | 0.00% | 51,440 |
24-04-24 | 0.08 | +6.67% | 440,300 |
24-04-23 | 0.075 | 0.00% | 118,919 |
24-04-22 | 0.075 | -6.25% | 280,373 |
Delayed Quote Toronto S.E., April 26, 2024 at 01:56 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.08% | 23.61M | |
+35.04% | 5.92B | |
-15.13% | 4.51B | |
-9.75% | 3.15B | |
+2.14% | 3.1B | |
-6.82% | 2.42B | |
+47.87% | 1.97B | |
-7.89% | 1.68B | |
+0.09% | 1.65B | |
-12.97% | 1.53B |
- Stock Market
- Equities
- LABS Stock